<div><p>When seconds matter, a rescue inhaler could be the difference between life and death.</p><p>A nationwide recall has been announced for inhalers produced by GlaxoSmithKline. Almost 600,000 inhalers are affected by the recall due to a defective delivery system. </p><p>The FDA has reported that some inhalers were "out of specification results for leak rate."</p><div><figure><amp-img src="https://www.shared.com/content/images/2017/04/image-1.jpg" srcset="https://www.shared.com/content/images/2017/04/image-1_GH_content_550px.jpg 550w" sizes="89vw" title="" alt="" height="9" width="16" layout="responsive"></amp-img><figcaption class="op-vertical-center"><cite>CTV Winnipeg</cite></figcaption></figure></div><p><!-- [invalid-shortcode] --></p><p>The recall doesn't pose an immediate danger to patients, but consumers are being instructed to return the purchased inhalers. </p><p>The affected product includes: Ventiolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 metered inhalations, net weight 18 g inhalers, RX only.</p><p>"We currently don't anticipate a supply impact to Ventolin HFA 200D inhaler as a result of this issue," <a href="http://www.foxnews.com/health/2017/04/05/drugmaker-recalls-nearly-600000-asthma-inhalers-in-us.html">GSK said</a> in a statement, according to Reuters. </p></div>